None
Quote | Kezar Life Sciences Inc. (NASDAQ:KZR)
Last: | $0.7915 |
---|---|
Change Percent: | -1.24% |
Open: | $0.8002 |
Close: | $0.8014 |
High: | $0.805 |
Low: | $0.773 |
Volume: | 484,625 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Kezar Life Sciences Inc. (NASDAQ:KZR)
2024-03-16 06:56:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Penny stocks provide risk and profit but frequently lie in the shadows in the fast-paced world of investing. Nevertheless, three-penny stocks stand like diamonds in the dust among the chaos...
2024-03-14 17:50:12 ET More on Kezar Life Sciences Seeking Alpha’s Quant Rating on Kezar Life Sciences Historical earnings data for Kezar Life Sciences Financial information for Kezar Life Sciences Read the full article on Seeking Alpha For fur...
Message Board Posts | Kezar Life Sciences Inc. (NASDAQ:KZR)
Subject | By | Source | When |
---|---|---|---|
As an update . After doing more research | Whalatane | investorshub | 04/04/2023 6:11:19 PM |
Yahoo finance today reporting market cap at $271.2 | Whalatane | investorshub | 03/16/2023 5:27:34 PM |
Well I obviously should have waited until after | Whalatane | investorshub | 03/16/2023 2:38:49 PM |
Buying at these levels . Their LN | Whalatane | investorshub | 03/13/2023 3:36:07 PM |
For the record ...not that anyone reads this | Whalatane | investorshub | 01/19/2023 10:31:02 PM |
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
Koninklijke KPN NV (KKPNF) is expected to report for Q4 2023 ECA Marcellus Trust I Unit (ECTM) is expected to report for Q4 2023 San Juan Basin Royalty Trust (SJT) is expected to report for Q4 2023 Avenir Wellness Solutions Inc (AVRW) is expected to report for Q4 2023 Carmell Corp...